肠道菌群
肾
微生物群
肾病
免疫学
免疫系统
炎症
肠道通透性
生物
医学
内科学
生物信息学
内分泌学
糖尿病
作者
Renato C. Monteiro,Laureline Berthelot
出处
期刊:Current Opinion in Gastroenterology
[Ovid Technologies (Wolters Kluwer)]
日期:2021-09-03
卷期号:37 (6): 565-571
被引量:17
标识
DOI:10.1097/mog.0000000000000789
摘要
Growing evidence show the importance of gut/kidney axis in renal diseases. Advances in gut microbiome sequencing, associated metabolites, detection of gut permeability and inflammation provide new therapeutic strategies targeting gut for kidney diseases and particularly for Immunoglobulin A (IgA) nephropathy (IgAN).The diversity and composition of gut flora have been recently deeply explored in kidney diseases. Modulation and depletion of microbiota in animal models allowed the understanding of molecular mechanisms involved in the crosstalk between gut, immune system and kidney. New clinical trials in order to positively modulate microbiota result in improvement of gastrointestinal disorders and inflammation in patients suffering with kidney diseases.The investigation of gut alterations in kidney diseases open new therapeutic strategies. In IgAN, targeted treatments for intestinal inflammation and modifications of gut microbiota seem promising.
科研通智能强力驱动
Strongly Powered by AbleSci AI